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Inducible Lineage-Specific Deletion of TbRII in
Fibroblasts Defines a Pivotal Regulatory Role during
Adult Skin Wound Healing
Christopher P. Denton1, Korsa Khan1, Rachel K. Hoyles1, Xu Shiwen1, Patricia Leoni1, Yunliang Chen1,
Mark Eastwood1 and David J. Abraham1
Previous attempts to delete type II TGFb receptor (TbRII) in fibroblasts have precluded examination of adult
mice due to early mortality. We have selectively deleted TbRII postnatally in differentiated connective tissue
fibroblasts using an inducible Cre-Lox strategy. Tamoxifen-dependent Cre recombinase linked to a fibroblast-
specific regulatory sequence from the proa2(I)collagen gene permitted deletion of floxed TbRII alleles. After
postnatal deletion of TbRII in fibroblasts, healing of excisional skin wounds in adults showed markedly
attenuated dermal scar formation, defective wound contraction and enhanced epidermal proliferation. These
findings support a pivotal role for transforming growth factor b (TGFb) signalling in fibroblasts in regulating
normal skin wound healing. Explanted dermal fibroblasts from TbRII-null-fib mice showed impaired migration
and did not generate normal contractile biomechanical forces in fixed collagen gels nor develop
a-smooth muscle antigen-rich stress fibers in response to TGFb1. Surprisingly, some TGFb-regulated proteins,
including connective tissue growth factor (CTGF), were basally upregulated in TbRII-null fibroblasts and this
was dependent on extracellular signal-regulated kinase 1/2 activity in these cells. This suggests that other
intracellular pathways regulating CTGF expression may partially compensate for disruption of TGFb signalling in
fibroblasts. Together, our data confirm that expression of TbRII in differentiated dermal fibroblasts is essential
for normal wound healing and demonstrate a critical role in the development and function of myofibroblasts.
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INTRODUCTION
Transforming growth factor b (TGFb) isoforms, acting via
specific high-affinity receptors (TbR), have a critical role in
normal embryonic development, connective tissue growth
and immunoregulation (Mishra et al., 2005; Wan and Flavell,
2007). Abnormal TGFb activity is implicated in the patho-
genesis of fibrosis (Mauviel, 2005) and neoplasia (Levy and
Hill, 2006). Previous studies have explored the biology of
TGFb using gene-targeted mice. For example, deletion of
TGFb1 results in embryonic lethality in approximately half
of the embryos, and those pups that are born alive eventually
die from multisystem inflammatory disease (Kulkarni et al.,
1993). TGFb2- and TGFb3-deficient mice die perinatally with
non-overlapping phenotypes. TGFb2-null mice have multiple
defects in visceral development (Sanford et al., 1997) and
TGFb3-null mice have abnormalities in palatal development
and epithelial–mesenchymal interaction (Proetzel et al.,
1995).
Triggering of downstream signalling events by TGFb
occurs via a complex of type I and type II TGFb receptors
and involves canonical Smad-dependent pathways (reviewed
in Massague et al., 2005). There is also Smad-independent
signalling via other pathways including stress-activated
kinases (mitogen-activated protein kinase), notably p38
mitogen-activated protein kinase, extracellular signal-regu-
lated kinase (ERK) and c-Jun N-terminal kinase, and small
GTPases such as Ras (Moustakas and Heldin, 2005). This
repertoire of signalling pathways with potential cross-talk
involving other agonists has made the role of individual
signalling components hard to delineate in vivo.
The high-affinity type II TGFb receptor (TbRII) has a central
role in mediating the biological effects of TGFb ligands. It is
the first high-affinity receptor to engage ligand at the cell
surface and directly regulates activation of type I receptor
(TbRI) (Feng and Derynck, 2005). TbRII may also form
complexes with other TGFb superfamily receptors to activate
intracellular signalling pathways (Miyazono et al., 2001).
Deletion of TbRII in vivo is a potentially powerful strategy
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for disruption of TGFb signalling. Consistent with this,
conventional germline deletion of TbRII is lethal in early
embryonic development due to defective yolk sac angiogen-
esis (Oshima et al., 1996). This has prompted the develop-
ment of lineage-specific strategies for deletion to explore the
consequences of absent TGFb signalling in single cell types
or tissue locations including lymphocyte (Cazac and Roes,
2000), bone marrow (Leveen et al., 2005), and cartilage
specific deletion (Baffi et al., 2004). Recent studies using a
Cre-Lox strategy to delete TbRII in vascular smooth muscle
cells or endothelial cells also led to embryonic lethality
(Carvalho et al., 2007). One potential confounder of prenatal
deletion is that compensatory mechanisms may mask the
effects of gene loss in complex and overlapping signalling
pathways. Another important consideration is that deletion of
genes that are critical for normal growth and development
may be lethal even when they are absent in specific cell
types. For example, after fibroblast-specific deletion during
embryonic development, using the fibroblast-specific
protein-1 promoter (Strutz et al., 1995) to direct expression
of Cre recombinase, mice showed high mortality within the
first month of life from epithelial malignancy (Bhowmick
et al., 2004; Cheng et al., 2005). A further refinement of the
lineage-specific approach is the technique of inducible
lineage-specific genetic recombination. This can be achieved
using ligand-dependent forms of Cre recombinase, generally
fusion proteins linking the catalytic domain of the enzyme to
a steroid hormone receptor that may be modified to restrict
ligand binding (Metzger et al., 1995). The combination of
tissue-directed expression using a lineage-specific promoter
and inducible genetic recombination is particularly powerful
(Schuler et al., 2005). For TbRII, there has been one report
using such a system to induce deletion of TbRII in the
epidermis of the head and neck region using an inducible
form of Cre recombinase linked to a keratin 5 promoter,
which demonstrates that loss of this receptor exacerbates
head and neck carcinoma (Lu et al., 2006).
In this study, we have used a fibroblast-specific expression
vector, incorporating a potent lineage-specific far upstream
enhancer from the proa2(I)collagen gene, linked to indu-
cible Cre (Zheng et al., 2002) to selectively delete TbRII in
differentiated fibroblasts postnatally. Thus, we have con-
firmed a critical role for TbRII in normal connective tissue
repair in vivo. Our results show that although full-thickness
wounds heal, there are profound abnormalities in contraction
and scar formation and associated epidermal changes. A key
feature is impaired myofibroblast differentiation and function.
This work delineates a critical role for TbRII in regulating the
activation of connective tissue fibroblasts for normal healing
and confirms the feasibility of inducible lineage-specific gene
targeting in fibroblasts.
RESULTS
Efficient postnatal fibroblast-specific deletion of TbRII in vivo
Mice homozygous for floxed TbRII allele (TbRIIflx/flx) were
crossed with mice harboring the Col1a2-Cre-ERT transgene
(Figure 1a). The Cre-ERT fusion protein is active only in the
presence of tamoxifen. Progeny were backcrossed to give a
strain in which all alleles of TbRII were floxed in the context
of heterozygosity for Cre-ERT. Initial experiments explored
the deletion of the target allele during embryonic develop-
ment. Pregnant females were injected with 1mg tamoxifen
at 12 days post conception. When litters were born, the
pups with the Cre-ERT transgene died within 1–6 hours
but those without the Cre transgene were viable. Thus in a
series of three consecutive litters, there were 16/27 (59%)
deaths in the Cre-ERT TbRIIflx/flx matings compared with
3/29 (10%) in control matings in which pregnant females
were injected with tamoxifen. PCR examination of genomic
DNA from tail biopsies confirmed deletion of the floxed
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Figure 1. Inducible fibroblast-specific deletion of TbRII. (a) A transgenic
strain was generated in which tamoxifen-dependent Cre recombinase is
expressed under the control of a fibroblast-specific expression cassette
(Col1a2-Cre-ERT) and both alleles of TbRII were conditionally inactivatable
due to LoxP sites flanking exon 4 (TbRIIflx/flx). When treated with tamoxifen,
genetic recombination occurred in fibroblasts to generate the null allele
(TbRII-null). (b) Neonatal compound mutant mice (Col1a2-Cre-ERT/TbRIIflx/
flx) were treated with intraperitoneal tamoxifen or corn oil vehicle control.
PCR analysis of tail DNA (derived from fibroblasts and non-fibroblastic cells)
confirms that a 692 bp PCR product from the null allele (P3, P5) is present
only after tamoxifen administration. A 575bp product from the non-
recombined allele is also present (P3, P4). (c) Lysates from fibroblasts cultured
from skin biopsies after tamoxifen administration confirm the absence of TbRII
protein. Control lanes show Coomassie staining of gel and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) immunolocalization. (d) Explanted skin
fibroblasts from TbRII-null-fib show no significant immunostaining for TbRII
compared with littermate wild-type fibroblasts. Nuclei are counterstained
with DAPI. (e) Skin from mice aged 3 weeks shows scattered cells within the
dermis expressing TbRII in wild-type control mice treated with corn oil
(f, arrows) whereas no dermal staining is present in mice that had received
tamoxifen in the neonatal period (bar¼ 100mm).
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allele. To circumvent the effect of embryonic deletion,
subsequent experiments administered tamoxifen or corn oil
control to compound mutant progeny postnatally. Represen-
tative genotyping PCR results after postnatal tamoxifen are
shown in Figure 1b.
Fibroblasts were cultured from skin 48 hours after comple-
tion of tamoxifen administration, and western blot examina-
tion confirmed deletion of TbRII in compound mutant
progeny (Figure 1c). Immunostaining of cultured fibroblasts
showed that specific TbRII immunoreactivity was absent in
fibroblasts from tamoxifen-treated mice compared with
littermate control cultures (Figure 1d).
Data for cultured fibroblasts were extended by analyzing
sections from adults and neonatal mouse skin. In neonatal
wild-type skin, there was widespread dermal expression of
TbRII whereas it was absent in TbRII-null-fib littermates. By
4–6 weeks of age, when experimental wounding was under-
taken (see below), expression in wild-type skin was much
more focal and was essentially absent in the dermis of
compound mutant mice (Col1a2-Cre-ERT/TbRIIflx/flx) that
had received tamoxifen (Figure 1e). Using semiquantitative
analysis, these differences were found to be highly statisti-
cally significant (8.8±1.3 vs 2.7±1.1 cells per high-power
field (hpf), P¼0.0003). In contrast, expression of TbRII in
non-fibroblastic cells of the muscularis layer was indistin-
guishable between mice treated with tamoxifen or corn oil
(6.2±1.3 vs 7.5±1.0, P¼0.54). There was no excess
of tumors of the gastrointestinal or urogenital tracts in
this mouse strain in contrast to recent reports of mice in
which TbRII was deleted using fibroblast-specific protein-1-
Cre (Bhowmick et al., 2004).
Explanted dermal fibroblasts lacking TbRII show impaired
response to TGFb1
Key biochemical properties of wild-type or TbRII-deleted
fibroblasts cultured from skin of littermate mice are summari-
zed in Figure 2a. There were clear differences in the
expression of TGFb-upregulated proteins in fibroblasts lack-
ing TbRII and impaired induction of these proteins by
recombinant TGFb1. This was seen for plasminogen-activator
inhibitor-1 (PAI-1), fibronectin, type I procollagen, and
connective tissue growth factor (CTGF), and similar differ-
ences were also seen for mRNA analysis by northern blot
(data not shown). There was strong constitutive expression of
a-smooth muscle antigen (aSMA) in wild type and marginally
lower expression basally in TbRII-null fibroblast strains. In the
supernatants of cultured fibroblasts, CTGF was only detect-
able in wild-type cultures after pretreatment with TGFb1 but
was entirely absent in TbRII-deleted fibroblast supernatants
(data not shown). In contrast, CTGF was present in the
fibroblast cell layer of both wild-type and TbRII-null cultures
and, surprisingly, basal levels were consistently found to be
two- to fourfold greater in fibroblasts lacking TbRII compared
with littermate wild-type cultures using densitometric quan-
tification. To extend protein and mRNA expression data that
pointed toward reduced TGFb responsiveness in fibroblasts
cultured from TbRII-null mice, a series of transient transfec-
tion experiments were performed using promoter-reporter
constructs that incorporated TGFb-responsive sequences
including PAI-1-luciferase, 3TP-luciferase, and CAGA-luci-
ferase (Figure 2b). For all three constructs, there was strong
upregulation in wild-type cells at 24 hours after stimulation
by TGFb1, but responses in TbRII-null fibroblasts were
essentially absent for PAI-1-luciferase and 3TP-luciferase
and attenuated for CAGA–luciferase.
We expected that dermal fibroblast explant cultures would
show altered activity of downstream signalling pathways after
deletion of TbRII in vivo. Therefore, we assessed the levels of
phosphorylated signalling intermediates involved in Smad-
dependent (phospho-Smad2) and Smad-independent (phos-
pho-ERK1/2, phospho-c-Jun N-terminal kinase, phospho-p38)
signalling. As expected, following TGFb1 stimulation, there
was no increase in phospho-Smad2 expression in fibroblast
lysates from TbRII-null-fib mice whereas littermate wild-type
cells showed induction at 30minutes. Although mitogen-
activated protein kinase activation by TGFb1 was attenuated
in TbRII-null fibroblasts, increased basal phosphorylation of
ERK1/2 was consistently observed (Figure 3a). These results
suggest that increased activation of ERK1/2 may underlie
constitutive overexpression of CTGF by fibroblasts after
deletion of TbRII in vivo. Immunostaining of fibroblasts
confirmed western blot results, with increased nuclear and
cytoplasmic expression of phospho-ERK1/2 in TbRII-null
fibroblasts (Figure 3b).
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Figure 2. Fibroblasts are refractory to recombinant TGFb1 after deletion of
TbRII. (a) Expression of key TGFb-regulated proteins was explored, including
PAI-1, aSMA, type I collagen, fibronectin, and CTGF. Constitutive and TGFb1
(2 ngml1, 16 hours)-treated fibroblasts are compared. Basal CTGF level was
elevated in the cell layer of fibroblasts lacking TbRII, but these cells were
refractory to TGFb1 stimulation. (b) Transient transfection of three
TGFb-regulated reporter plasmids confirms reduced responsiveness of
TbRII-null-fib dermal fibroblasts to recombinant TGFb1. Data are
representative of three independent experiments for each construct. Units
are in RLU (±SD) corrected for transfection efficiency. Basal values were
compared with activity after TGFb1 activation (***Po0.005; **Po0.01;
*Po0.05, paired Student’s t-test). See Materials and Methods for details
of the reporter constructs.
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Defective skin wound healing in mice following
fibroblast-specific deletion of TbRII
There was a striking difference between the healing of full-
thickness skin wounds in wild-type and those in TbRII-null-
fib mice (Figure 4a). At 3 days, wild-type animals show clear
evidence of healing with re-epithelialization and flattening of
the wound contour. In contrast, wounds in TbRII-null mice
remained well demarcated at 3 days. By 7 days, wild-type
skin had almost completely re-epithelialized and there was
significant dermal regeneration and contraction of the wound
with apposition of the muscularis layer, linked by fibrous
and cellular granulation tissue. Overall, the most striking
features of TbRII-null-fib skin wounds at 7 days were an
almost complete absence of dermal regeneration, a failure of
the wound to contract, and diminished fibrillar collagen and
extracellular matrix deposition (data not shown). By 14 days,
healing in wild-type skin was almost complete. In contrast,
the TbRII-null-fib wound was still very prominent and newly
formed cellular connective tissue filled the defect within the
dermis. Measurement of the diameter in a series of skin
wounds confirmed a marked persistence of the visible scar
after experimental skin wounding in TbRII-null-fib mice
compared with wild-type controls (Figure 4b). For wild-type
wounds, at 14 days mean (±SD) diameter was 0.57mm
(±0.29) compared with 1.75mm (±0.28) for TbRII-null-fib
wounds (P¼0.001). Absence of nuclear staining for estrogen
receptor (ER) in fibroblasts (Estrach et al., 2006) confirmed
that Cre-ERT is not likely to be active at the time of skin
wounding (data not shown).
Deletion of TbRII in dermal fibroblasts promotes epidermal
proliferation in healing wounds
There were marked differences in cellular architecture,
proliferation, and TGFb ligand and receptor expression in
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Figure 3. Perturbed signalling with increased basal ERK1/2 phosphorylation
after TbRII deletion. (a) There was no increase in Smad2 phosphorylation at
30minutes after TGFb1 simulation in fibroblasts lacking TbRII. Basal
phosphorylation of ERK1/2 was increased in these fibroblasts and induction
was delayed compared with wild-type control littermates. Data are
representative of a series of three independent studies. (b) Immunostaining of
dermal fibroblasts confirms increased phospho-ERK1/2 in TbRII-null cells
compared with wild type. The inset shows staining of nuclei with DAPI.
Data are representative of three independent studies (bar¼ 50mm).
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Figure 4. Defective wound healing in TbRII-null-fib mice. (a) Representative
wound cross-sections stained by hematoxylin and eosin comparing TbRII-
null-fib mice with wild-type littermates. Key abnormalities in TbRII-null-fib
included the lack of any subdermal granulation tissue and scar at 7 days and
absence of a fibrous dermal scar at 14 days, with replacement of the dermal
defect by cellular granulation tissue at this time point. Data are representative
of three independent studies each with at least two wild-type or mutant
littermate mice at each time point (bar¼ 100mm). (b) Differences between
macroscopic healing of 4mm punch wounds on the lower back are
confirmed by measuring maximum wound diameter, which was significantly
larger at 7 and 14 days in TbRII-null-fib mice. Data summarize a series of
wounds at three time points, each time point summarizing data from 3 to 6
wild-type or mutant littermate mice at each time point.
www.jidonline.org 197
CP Denton et al.
Inducible Deletion of TbRII in Fibroblasts
the epidermis of healing wounds in TbRII-null-fib mice
compared with wild-type control littermate animals. Staining
with 4,6-diamidino-2-phenylindole (DAPI) (Figure 5a and b)
showed altered epithelial architecture. In uninjured wild-type
skin there was a multilayered epidermis, whereas the null
skin epidermis had a much thinner structure. After wounding,
re-epithelialization was complete in both wild-type and null
mice by 7 days. However, at this time point, there were
distinct differences between wild-type and mutant skin. To
delineate the differences in cellular proliferation, the marker
Ki-67 was examined by immunostaining. Consistent with the
differences in cellular architecture in the epidermis of the
healing skin, more cells in the epidermis expressed Ki-67 in
the TbRII-null-fib wounds (Figure 5c and d). Quantification of
the expression in the basal epidermal cells confirmed more
than twofold more proliferating keratinocytes per hpf in
TbRII-null-fib wounds (37.0±7.1 per hpf) compared with
wild type (14.7±2.5 per hpf, P¼0.006) at 7 days. In wild-
type wounds, at 7 days there was also marked expression of
this marker in the cell-rich granulation tissue, whereas
expression in the dermis of the TbRII-null wound was
confined to the wound edges. In addition to increased
proliferation, there was also more extensive expression of
TbRII and TGFb1 ligand on the healing epidermis of TbRII-
null-fib mice (Figure 5e and f) than wild-type control animals
(Figure 5f and h), perhaps reflecting an aberrant interplay
between dermal and epidermal TGFb ligand–receptor axis in
skin wound healing.
Impaired fibroblast migration and myofibroblast differentiation
underlie defective wound contraction after deletion of TbRII in
resident dermal fibroblasts
Expression of aSMA, a phenotypic marker of myofibroblasts,
was examined in the healing wounds at three time points.
Positive staining was confined to microvessel walls adjacent
to the wound at 3 days (data not shown). At 7 days, there was
strong aSMA expression in granulating wild-type wounds,
and this was observed within fibroblastic cells as well as the
walls of small blood vessels (Figure 6a). In contrast, TbRII-
null-fib skin showed aSMA expression largely confined to
vascular structures at the edge of the dermal defect, with no
expression in the deeper layers of the dermis (Figure 6b).
Interestingly, there was also subepidermal aSMA immuno-
staining in fibroblastic cells of mouse wounds, and this was
seen in both wild-type and mutant mice. To investigate
whether these cells might be derived from circulating bone
marrow-derived fibrocytes, representative sections were
simultaneously immunostained for the markers CD34 and
aSMA. In both wild-type and TbRII-null-fib wounds, there
were clusters of fibroblast-like cells beneath the epidermis
that expressed CD34 (Figure 6f). Coexpression of CD34 and
aSMA was present in some cells, and this was particularly
prominent in the TbRII-null-fib wound. As expected, these
cells also showed expression of TbRII (data not shown).
To further elucidate the mechanism underlying defective
wound healing in mice lacking TbRII on dermal fibroblasts,
we investigated fibroblast migration and myofibroblast-
dependent collagen gel contraction in vitro. Migration of
TbRII-null fibroblasts was explored in two in vitro assays. The
scratch wound assay allows direct visualization of fibroblast
migration, which was consistently deficient in the mutant
fibroblasts compared with littermate wild-type fibroblasts.
Representative examples of migration at 48 hours are shown
in Figure 7a. Contraction of free-floating fibroblast-populated
collagen lattices (FPCLs) depends on fibroblast migration
within the gel and interaction between fibroblasts and
collagen via integrins on the cell surface. Unstimulated
gel contraction was diminished in TbRII-null fibroblasts
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Figure 5. Fibroblast-specific deletion of TbRII is associated with increased
epidermal proliferation. Postnatal deletion of TbRII in fibroblasts led to
marked alteration in epidermal architecture at the site of full-thickness skin
wounds. The panels show healing wounds at 7 days. (a) In wild-type skin,
there was a well-organized multilayer epidermis with flattening of maturing
keratinocytes at the skin surface and a well-organized 3- to 4-cell thick layer
of mature cells. (b) Null mice had a much less organized multicellular
epidermis without apparent maturation of keratinocytes and dense cellular
aggregates in the basal layer. (c) The proliferation marker Ki-67 was expressed
sporadically at this site in healing wild-type skin, but was much more
uniformly present in null skin (d). Expression of TbRII is restricted to the
central epidermis of wild-type wounds (e) compared with much more
extensive expression (arrow) in null skin (f). Similarly, strong expression of
TGFb1 in wild-type skin is largely restricted to the basal epidermis in
wild-type wounds (g) compared with staining throughout the epidermis
(arrow) in null littermates (h). Data are representative of a series of three
independent experiments. Original magnification for photomicrographs
is indicated (bar¼ 50mm (a–d, g, h), 100 mm (e, f)).
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compared with those from wild-type littermate control skin,
and in null cells not significantly stimulated by recombinant
TGFb1. With wild-type fibroblasts, there was greater basal
contraction and contraction of the collagen lattice was
markedly greater in the presence of TGFb1. Thus, induction
of contraction by recombinant TGFb1 was significantly
diminished in the mutant fibroblasts (Figure 7b). These
findings support the hypothesis that abnormal fibroblast
migration in vivo may be central to the defective wound
healing in TbRII-null mice.
In vivo and in vitro expression patterns of aSMA suggested
that myofibroblast differentiation was likely to be impaired in
fibroblasts lacking TbRII. To assess the functional conse-
quence of this, contraction of tethered FPCLs was examined
and the contractile force generated over 24 hours was
measured (Figure 7c). In the absence of exogenous TGFb1,
there was a slower rate of contraction and reduced maximal
force for TbRII-null fibroblasts. For wild-type cells, fixed gel
contraction was stimulated by TGFb1, with a sustained
increase in contraction being particularly prominent from
6hours. In contrast, fibroblasts from TbRII-null-fib skin did
not generate enhanced tissue culture forces even after the
addition of recombinant TGFb1. There was a steady fall in
lattice tension between 8 and 24 hours, with no difference
between TGFb1-treated and nontreated mutant fibroblasts
between the 12 and 24 hours time points that are known to be
primarily dependent on contractile forces arising from
differentiated myofibroblasts within the gel lattices in this
experimental system (Tomasek et al., 2002).
Based on the data from our in vivo studies of skin wounds,
we hypothesized that, despite the presence of near-normal
levels of aSMA in fibroblast lysates assayed by western blot
(Figure 2), the absence of TbRII prevented the assembly of
aSMA-rich contractile myofibrils. This was confirmed by
immunostaining that compared wild-type and TbRII-null-fib
fibroblasts after stimulation by recombinant TGFb1. Wild-
type fibroblasts grown on glass slides develop a dense
network of actin-rich stress fibers that stain strongly for aSMA
(Figure 8a and c), whereas this is much less apparent in TbRII-
null fibroblasts. Actin-containing cytoskeletal filaments are
present but these do not contain aSMA. These findings
confirm a profound abnormality in myofibroblast differentia-
tion or function in fibroblasts lacking TbRII (Figure 8b and d),
which can be assumed to underlie defective healing and
contraction of full-thickness skin wounds in these animals.
Differences between fibroblast lysate levels and whole-cell
immunostaining of aSMA are also likely to reflect methodo-
logical differences including the greater sensitivity of western
blotting for detecting aSMA protein.
Taken together, our results confirm the importance of
intact TGFb signalling in resident dermal fibroblasts for
normal wound healing in vivo, and provide strong evidence
for functional cross-talk between fibroblasts and epidermal
cells that depends on TGFb receptor expression.
DISCUSSION
In this study, we have used an embryonically defined
fibroblast-specific regulatory sequence of the proa2(I)colla-
gen gene to selectively delete TbRII in differentiated
connective tissue fibroblasts postnatally in mice. This work
extends and complements earlier studies that used fibroblast-
specific expression of Cre-ERT to activate a reporter gene in
fibroblasts (Zheng et al., 2002) or to turn on expression of a
constitutively active variant of the type I TGFb receptor
(Sonnylal et al., 2007). Thus, we have generated mice in
which TGFb responses in fibroblasts are specifically blocked
by postnatal genetic recombination. This strategy has
permitted robust in vivo analysis of the role of TbRII in
connective tissue fibroblasts in adult mice. We have used this
approach to confirm a pivotal role for TbRII in fibroblasts for
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Figure 6. Impaired recruitment and differentiation of myofibroblasts in vivo
after deletion of TbRII. There was high-level expression of aSMA in the dense
subdermal granulation tissue of healing punch wounds at 7 days in wild-type
mice compared with the TbRII-null-fib strain at low magnification (a, b).
Higher magnification views show that expression within myofibroblastic cells
within the granulation tissue (m, arrow(c, d)). Expression in the wounds of
TbRII-null-fib mice was less and was mostly located in vascular structures (v).
The lower panels are high-power views to show clusters of aSMA-expressing
cells (pink) immediately beneath the epidermis of healing wounds at
7 days (e, f). These were more prominent in TbRII-null-fib mice. Some of these
cells (magnified inset) also expressed CD34 (brown stain), suggesting that they
are bone marrow-derived fibrocytes (c, arrow). Data are representative of
three independent studies (bar¼100 mm (a–d), 50 mm (e, f)).
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the repair and regeneration of skin after experimental
wounding. In particular, it appears that in the absence of
TbRII, fibroblast migration and myofibroblast differentiation
are markedly impaired. In addition, we observed attenuated
induction of extracellular matrix synthesis in fibroblasts
cultured from TbRII-null-fib in response to recombinant
TGFb1 and identified constitutive changes in mitogen-
activated protein kinase signalling in these cells.
As our strategy targets differentiated fibroblasts in the
postnatal period, it permits evaluation of the role of resident
dermal fibroblasts in connective tissue turnover and wound
repair. We expect that fibroblastic cells derived from
alternate lineages after skin injury, such as circulating
progenitor cells (fibrocytes) (Bellini et al., 2007) or epithelial
cells (epithelial–mesenchymal transformation) (Davies et al.,
2005), would still be recruited to the wound. In the absence
of tamoxifen, TGFb signalling is expected to be intact in these
cells after differentiation to fibroblasts. This is important as
earlier work suggested that a substantial number of fibro-
blastic cells in healing skin wounds are derived from the bone
marrow (Bellini et al., 2007). The presence of aSMA-positive
cells just beneath the epidermis in some 7-day wounds in
TbRII-null-fib mice is consistent with other recent studies
(Yamaguchi et al., 2007), and our study clearly demonstrates
clusters of subepidermal cells expressing CD34 and aSMA
likely to be derived from circulating fibrocytes. Taken
together, our results suggest that although recruitment of
these cells is preserved and they may contribute to the
healing process, they are not sufficient to rescue normal
healing and wound contraction in the TbRII-null-fib strain.
Central to the interpretation of our findings is the
completeness of deletion of TbRII in resident connective
tissue fibroblasts following neonatal administration of tamox-
ifen in compound mutant progeny. Although it is possible
that deletion of TbRII did not occur in all fibroblasts,
earlier histological studies suggest that the far upstream
enhancer from proa2(I)collagen is activated in all fibroblasts
during embryonic development and in mice until 4 weeks
postnatally (Denton et al., 2001). Assessment of the
completeness of deletion in vivo is challenging because
TbRII is normally only expressed in a subset of fibroblasts
in unwounded skin of healthy adult mice. Expression appears
to be absent in fibroblasts in TbRII-null-fib but intact in
other cell types within the skin. Tissue culture studies suggest
that in vivo deletion was efficient as there is negligible
expression of TbRII in fibroblasts in monolayer culture
Wild type
Wild type
Null
Null
Wild type Null
0 hour
48 hours
0 hour
48 hours
P=0.03
P=0.03
P=0.01
120
100
80
60
40
20
350
300
250
200
150
100
50
0
0
50
100
150
200
250
300
0
G
ap
 s
ize
 (%
)
Fo
rc
e 
(dy
ne
s)
G
el
 w
ei
gh
t (m
g)
Basal TGFβ1
TGFβ1
Null/TGFβ1
wt/TGFβ1
Null
wt
4 8 12 16 20 24
Time (hours)
Figure 7. TbRII-null fibroblasts show impaired migration and collagen gel matrix contraction. (a) The scratch wound assay allowed direct evaluation of
migration in vitro. Migration was reduced for fibroblasts lacking TbRII, as shown in the histogram summarizing three independent experiments with initial
wound width taken as 100%. (b) TbRII-null fibroblasts showed reduced basal contraction of free-floating collagen lattices and were refractory to recombinant
TGFb1. Mean (±SD) data summarize three independent experiments. (c) Tethered FPCLs confirm attenuated contraction for TbRII-deleted fibroblasts and
refractoriness to TGFb1. Data summarize two independent experiments with littermate fibroblast cultures. The arrow in the inset shows addition of recombinant
TGFb1 as outlined in Materials and Methods.
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whereas wild-type fibroblasts show uniform expression in
almost all cells.
Regulation of epithelial cell growth and differentiation by
fibroblasts is now well established, as is the potential for
epithelial cells to modulate fibroblast properties (Werner
et al., 2007). Such reciprocal interaction is likely to be central
to coordinated events in growth and development and in
tissue repair and regeneration. It is noteworthy that epidermal
expression of TGFb1 and TbRII is much more intense and
diffuse in the wounds of mice lacking TbRII in fibroblasts.
These observations are consistent with findings reported for
wound healing in other mutant mice, such as TGFb-depen-
dent epidermal changes in integrin b3-null mice. In conven-
tional knockout mice, there is deletion in all cell types and it
has not been easy to distinguish between direct and indirect
effects of gene deletion (Ashcroft et al., 1999, 2000). Lineage-
specific gene deletion allows such processes to be more
precisely defined. One possible explanation for upregulation
of the TGFb ligand–receptor axis in keratinocytes is a
reduction in TGFb-regulated mediators from dermal fibro-
blasts in mice after fibroblast-specific deletion of TbRII.
Overexpression of the matricellular protein CTGF by
skin fibroblasts from TbRII-null-fib mice is somewhat surpris-
ing as this is a hallmark TGFb-inducible protein. However,
our results suggest that these mutant fibroblasts are refractory
to TGFb induction of CTGF, with no induction in tissue
culture supernatants. It is known that in chronic fibrosis
upregulation of CTGF in fibroblasts is TGFb independent
and similar mechanisms may be relevant in our model
system. For example, in the chronic fibrotic disease
scleroderma, CTGF upregulation is associated with increased
activity of ERK1/2 (Stratton et al., 2002). Very recent work
suggests that CTGF may itself activate ERK1/2 signalling
(Wahab et al., 2007) and this may also be relevant to our
observations.
In conclusion, we have selectively deleted TbRII in
fibroblasts postnatally. The resultant mice show profoundly
abnormal healing of excisional skin wounds with failure of
wound contraction and fibrous scar formation, and increased
epidermal cell proliferation. Our findings confirm that
expression of TbRII in fibroblasts is essential for normal
wound healing. Similar strategies are likely to be invaluable
for exploring selective disruption of other components of
TGFb signalling in vivo.
MATERIALS AND METHODS
Generation of compound mutant mice for conditional deletion
of TbRII in fibroblasts
We have previously described generation of a mouse strain in which
expression of a tamoxifen-dependent Cre recombinase is targeted to
fibroblasts to permit lineage-specific genetic recombination at
defined time points (Zheng et al., 2002). The expression cassette
regulating this transgene incorporates a 6 kb fragment of a potent
fibroblast-specific far upstream enhancer from Col1a2 (19.5 to
13.5 kb) linked to a minimal endogenous promoter (350 to
þ 54bp). Previous studies have confirmed that this cassette directs
high-level expression to fibroblasts but not other type I collagen-
producing cells (Denton et al., 2001, 2005). Transgenic mice were
genotyped using a specific PCR for an internal ribosome entry site
sequence (Zheng et al., 2002). Mice harboring a conditional
inactivatable allele of TbRII were established using gene targeting
as described previously (Leveen et al., 2005). Genotype was
confirmed by two primers flanking the 50 loxP site (P3 TATGGAC
TGGCTGCTTTTGTATTC and P4 TGGGGATAGAGGTAGAAAGAC
ATA) and the null allele by primers P3 and P5 (P5 TATTGGGT
GTGGTTGTGGACTTTA). Specific PCR products of 575 or 692 bp
were detected. To establish compound mutant strains, the Cre-ERT-
fib strain was crossed with mice homozygous for the floxed TbRII
allele. Progeny harboring Cre-ERT and TbRII-flx were back-crossed
with the TbRIIflx/flx homozygous strain. Mice were treated with
tamoxifen (1mg per 50 ml) or corn oil vehicle, administered by daily
intraperitoneal injection for 5 days, starting at 10–14 days (Zheng
et al., 2002). Within all key experiments, controls included
compound mutant mice treated with corn oil or littermate mice
lacking the Cre-ERT-fib transgene that were injected with tamoxifen.
This design controlled for any potential effect of this transgene
product in the absence of ligand and also for possible direct or
indirect action of tamoxifen on fibroblast properties or wound
healing.
Wild type Null
a b
c d
Figure 8. Attenuated cytoskeletal incorporation of aSMA after deletion of
TbRII.Wild-type dermal fibroblasts showed more prominent aSMA-rich stress
fibers after treatment with recombinant TGFb1 (2 ngml1, 24 hours) using an
FITC conjugate (a), compared with fibroblasts cultured from TbRII-null-fib
littermates (b). The upper panels show aSMA stain of fibroblasts at low
magnification ( 10). Lower panels (c, d) are high-power ( 40) views.
Dermal fibroblasts from TbRII-null-fib skin show a normal cytoskeleton
(phalloidin-rhodamine conjugate) but few aSMA-rich stress fibers (FITC
conjugate). There was no consistent aSMA staining in the absence of
recombinant TGFb1. Data are representative of three independent
experiments (bar¼ 100mm (a, b) 50mm (c, d)).
www.jidonline.org 201
CP Denton et al.
Inducible Deletion of TbRII in Fibroblasts
Histological analysis
After overnight formalin fixation, tissues were processed and
embedded in paraffin, and 3–5mm sections were mounted onto
poly-L-lysine-coated microscope slides (VWR, UK). Before staining,
sections were de-waxed in xylene (Genta Medical, York, UK) and
passed through graded series of alcohol to water. Following staining,
sections were dehydrated with alcohol, cleared in xylene, and
mounted with a permanent mountant (DPX). For histology and
immunohistochemistry, sections were viewed and photographed
using a Zeiss Axioscope light microscope (Carl Zeiss, Germany) with
Axiovision software. Unless stated, reagents were purchased from
Raymond Lamb Ltd, Eastbourne, UK.
Fibroblast culture
Fibroblast cultures were derived from skin biopsies from the lower
back. Fibroblasts were maintained in DMEM (Invitrogen BRL,
Paisley, Scotland, UK) supplemented with 10% fetal calf serum
(Invitrogen, Grand Island, NY), 100Uml1 penicillin, 100mgml1
streptomycin, and cultured in a humidified atmosphere of 5% CO2
in air. All studies were performed using cultures between second and
fourth passages. Fibroblast monolayer cultures were incubated for
16–24hours in serum-free medium before examining agonist effects.
For immunostaining, fibroblasts were seeded into chamber slides.
Immunostaining of cells and tissues
Formalin-fixed paraffin-embedded mouse wound tissue sections cut
on poly-L-lysine-coated slides to a thickness of 3mm were depar-
affinized in xylene for 10minutes, dehydrated in alcohol, and
hydrated in distilled water. Nuclei were stained for 1minute in
1mgml1 DAPI (Molecular Probes, Eugene, OR) for fibroblast
immunofluorescent analysis and this was also used to assess
epidermal cellularity and architecture of fixed sections of skin. For
the detection of aSMA (catalog number M0851, Dako, Ely, UK), the
Mouse on Mouse kit (Vector Laboratories, Peterborough, UK) was
used. Nonspecific binding of the secondary antibody was blocked
using mouse immunoglobulin blocking (Vector Laboratories) in
phosphate-buffered saline (PBS, pH 7.4) for 1 hour. Optimally diluted
primary antibodies at a final concentration of 100mgml1 were added
to each section and incubated for 30minutes at room temperature.
Sections were washed and binding was detected using a biotin-
conjugated anti-mouse IgG (Vector Laboratories) and an alkaline
phosphatase-based detection system. Positive staining was visualized
using Vector Red substrate (Vector Laboratories) as a chromogen with
the addition of levamisole to block any endogenous alkaline
phosphatase activity. Similar protocols were used to stain for TbRII,
TGFb1, CD34, and the proliferation marker Ki-67 (catalog numbers
sc-400, sc-146, ab8158, and M7249, Santa Cruz Biotech (Santa Cruz,
CA), Abcam (Cambridge, UK), and Dako). Specificity of staining was
confirmed in control sections incubated with an isotype-matched
irrelevant control antibody at equivalent protein concentrations. Mean
number of positive cells per hpf was determined in representative
sections for quantification of TbRII and Ki-67 expression.
Double staining was undertaken for aSMA and CD34. In brief,
this involved sequential incubation with CD34 at a concentration of
2mgml1 overnight after microwave pretreatment in Tris-EDTA
buffer (pH 9). A pre-adsorbed biotinylated anti-rat secondary
mouse was subsequently used followed by visualization using
3, 3’-diaminobenzidine substrate. Slides were then stained for aSMA
using the MOM kit (Vector Laboratories, Burlingame, CA) followed
by an alkaline phosphatase-conjugated tertiary antibody. Develop-
ment was visualized using Vector Red substrate followed by
counterstaining with Mayer’s hematoxylin.
For immunostaining of dermal fibroblast cultures, cells were
seeded at 4 103 cells per well in DMEM–10% normal calf serum
into chamber slides (Becton & Dickinson, Oxford, UK), grown to
subconfluence, made quiescent in serum-free DMEM overnight, and
exposed to control media (DMEM) or recombinant TGFb1
(2–4ngml1) for 1–24hours. The cell monolayer was washed three
times with PBS and fixed in 4% formaldehyde for 5minutes. Cells
were washed three times in PBS. Chamber slides were incubated with
primary antibody specific for aSMA (Dako). After incubation
with primary antibody or irrelevant control serum, slides were treated
with a fluorescein-conjugated anti-mouse antibody (Vector Labora-
tories, Peterborough, UK), each for 60minutes at room temperature.
After extensive washing with PBS, a single drop of vectorshield
mountant with DAPI was added and cells were then visualized and
photographed using Axioskop Z fluorescence microscope (Carl Zeiss).
Transfection of dermal fibroblasts
To assess TGFb1 signalling pathway activity or responsiveness, a
series of TGFb-regulated promoter-reporter constructs were used as
described previously (Denton et al., 2005), including PAI-1-
luciferase, incorporating the proximal promoter of the plasminogen
activator inhibitor-1 gene; a trimeric sequence delineated as the
TGFb response element of this PAI-1 promoter, designated 3TP-
luciferase; and CAGA-luciferase incorporating a multimeric Smad-
binding motif driving a firefly luciferase reporter. All plasmids were
transfected into neonatal fibroblasts using Lipofectamine plus
(Invitrogen, Paisley, Scotland, UK). Assessment of luciferase activity
was by the Dual light reporter gene system (Tropix Inc., Bedford,
MA) with a 1:100 pSV40 control plasmid. For experiments, 70–80%
confluent fibroblast monolayers were used in 24-well tissue culture
plates.
Western blot analysis of fibroblast protein expression
Cell layer lysates and tissue culture supernatants were examined
from littermate pairs (n¼ 5). Supernatants were concentrated by
ammonium sulfate precipitation to selectively enrich samples for
secreted matrix proteins. Specific antibodies to collagen type I
(catalog number 20151, Novotec Laboratories, Saint Martin La
Garenne, France), CTGF (catalog number sc-14939, Santa Cruz
Biotech), fibronectin (catalog number F1141, Sigma, Poole, Dorset,
UK), aSMA (as previously mentioned), TbRII (as previously
mentioned), glyceraldehyde-3-phosphate dehydrogenase (catalog
number ab8245, Abcam), and phosphorylated Smad2 (catalog
number 3101, Cell Signaling Technology, Danvers, MA) or
phosphorylated ERK1/2 (catalog number 9101, Cell Signaling
Technology) were used. Quantification was performed using the
Gelplate computerized system for densitometric analysis of western
blot for equally loaded samples.
Contraction of free-floating or fixed FPCLs
Fibroblasts were cultured within three-dimensional collagen lattices
(FPCLs) (Tomasek et al., 2002). In brief, 24-well tissue culture plates
(Costar) were precoated with sterile 2% BSA in PBS (2ml per well)
by incubation at 371C overnight. For FPCLs, neutral collagen
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solution containing one part of 0.2 M HEPES (pH 8.0), four parts of
collagen (Vitrogen-100, 3mgml1, Celltrix, Santa Clara, CA), and
five parts of MCDB 104 medium (Sigma, two times concentrate) was
prepared and mixed with fibroblasts. After polymerization, 1ml of
MCDB medium was added to each well yielding free-floating
FPCLs.
Measurement of tension across a three-dimensional, free-floating
FPCLs was performed as described previously (Denton et al., 2005).
Briefly, with 1 106 cells per ml collagen gel, we measured the
force generated across the collagen lattice, by using a tensioning-
culture force monitor that is capable of measuring the minute forces
exerted by cells within a collagen lattice over 24 hours as fibroblasts
attach, spread, and migrate. Cell-generated tensional forces in the
collagen gel were detected by the force transducer. Graphical
readings are produced every 10minutes, averaged from 600
readings (1 per second), providing a continuous output of force
generated (dynes) (Tomasek et al., 2002).
Wound healing studies
Gender-matched littermates aged 6–10 weeks were examined. Control
animals included compound mutants that harbored the Cre-ERT
transgene and floxed TbRII alleles that were treated with corn oil
vehicle rather than tamoxifen, or littermates that lacked Cre-ER and
were treated with tamoxifen at the same time points as compound
mutant littermates. For excisional skin wound studies, animals were
anesthetized using intraperitoneal avertin and four full-thickness 4mm
skin wounds were formed using a sterile biopsy punch (Werner et al.,
2007). All procedures were carried out in accordance with Home Office
requirements. Animals were killed at 3, 7, and 14 days after wounding.
Scar size during healing was quantified by measuring the maximum
distance between the epidermal lip for each wound in anesthetized
mice and compared using standard methods (Eming et al., 2007).
In vitro scratch wound assay
A fibroblast monolayer scratch wound assay was used to further
explore fibroblast migration (Kole et al., 2005). The monolayer was
artificially injured by scratching across the plate with a pipette tip
(approximately 1.3mm width). After washing to remove detached
cells or cell debris, wells were cultured in serum-free medium.
Mitomycin C (10 mgml1) was included in the media to prevent cell
proliferation. Migration was determined relative to average gap at
1 hour after scratch wound, expressed as percent change using the
‘‘average gap’’ method (Li et al., 2004).
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